Future studies could evaluate whether the pharmacological induction of SMAD1 expression may represent a therapeutic strategy in KMT2A-rearranged AML with KMT2A::AFF1 and KMT2A::MLLT3 fusion genes. This evidence concerns the gene MLLT3 and acute myeloid leukemia.